Acquisition of Growth-Inhibitory Antibodies against Blood-Stage Plasmodium falciparum by McCallum, Fiona J. et al.
Acquisition of Growth-Inhibitory Antibodies against
Blood-Stage Plasmodium falciparum
Fiona J. McCallum
1,2, Kristina E. M. Persson
1, Cleopatra K. Mugyenyi
3, Freya J. I. Fowkes
1, Julie A.
Simpson
4, Jack S. Richards
1,2, Thomas N. Williams
3, Kevin Marsh
3, James G. Beeson
1*
1The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia, 2Department of Medical Biology, University of Melbourne, Parkville, Victoria,
Australia, 3Kenya Medical Research Institute, CGMRC/Wellcome Trust Collaborative Program, Kilifi, Kenya, 4Centre for Molecular, Environmental, Genetic and Analytic
Epidemiology, University of Melbourne, Carlton, Victoria, Australia
Abstract
Background: Antibodies that inhibit the growth of blood-stage Plasmodium falciparum may play an important role in
acquired and vaccine-induced immunity in humans. However, the acquisition and activity of these antibodies is not well
understood.
Methods: We tested dialysed serum and purified immunoglobulins from Kenyan children and adults for inhibition of P.
falciparum blood-stage growth in vitro using different parasite lines. Serum antibodies were measured by ELISA to blood-
stage parasite antigens, extracted from P. falciparum schizonts, and to recombinant merozoite surface protein 1 (42 kDa C-
terminal fragment, MSP1-42).
Results: Antibodies to blood-stage antigens present in schizont protein extract and to recombinant MSP1-42 significantly
increased with age and were highly correlated. In contrast, growth-inhibitory activity was not strongly associated with age
and tended to decline marginally with increasing age and exposure, with young children demonstrating the highest
inhibitory activity. Comparison of growth-inhibitory activity among samples collected from the same population at different
time points suggested that malaria transmission intensity influenced the level of growth-inhibitory antibodies. Antibodies to
recombinant MSP1-42 were not associated with growth inhibition and high immunoglobulin G levels were poorly predictive
of inhibitory activity. The level of inhibitory activity against different isolates varied.
Conclusions: Children can acquire growth-inhibitory antibodies at a young age, but once they are acquired they do not
appear to be boosted by on-going exposure. Inhibitory antibodies may play a role in protection from early childhood
malaria.
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Introduction
Plasmodium falciparum malaria is a leading cause of childhood
mortality, with around 1 million deaths annually [1]. In malaria-
endemic areas effective immunity against malaria develops after
repeated exposure that limits blood-stage parasitemia and prevents
symptomatic illness and severe complications [2]. Antibodies that
inhibit blood stage replication of P. falciparum are believed to be
important in mediating both acquired immunity and immunity
generated by candidate blood-stage vaccines [3,4,5]. Serum
antibodies that inhibit parasite growth in vitro have been isolated
from clinically immune individuals, but are rarely detected in
malaria-naı ¨ve individuals [3,5]. Early studies suggest that these
‘‘growth-inhibitory’’ antibodies are acquired in an isolate-specific
manner following convalescence from acute infection [6].
However, the role of growth-inhibitory antibodies in protection
from clinical disease in humans, or their function in vivo, has not
been established. Furthermore, there is limited knowledge of the
acquisition of these antibodies and it is unclear whether inhibitory
antibodies can be acquired quickly after limited exposure or
instead require repeated exposure over an extended period.
Inhibitory antibodies are thought to mainly act by inhibiting
erythrocyte invasion through targeting merozoite surface antigens
and invasion ligands [7,8]. Data from animal studies support an
important role for antibodies against merozoite antigens in
immunity [9,10]. Merozoite surface protein 1 (MSP1), apical
membrane antigen 1 (AMA1), erythrocyte binding antigens (EBAs)
and P. falciparum reticulocyte-binding homologues (PfRh proteins)
are implicated as important targets of acquired human inhibitory
antibodies [11,12,13,14], and polyclonal and monoclonal anti-
bodies produced in experimental animals against these antigens
can inhibit erythrocyte invasion in vitro [7,10,12,15,16,17]. Studies
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recombinant merozoite antigens and protective immunity
[18,19,20,21,22,23,24,25,26,27]. However, measuring antibodies
to recombinant merozoite proteins has significant limitations and
antibody reactivity in these assays may not reflect functional
activity. Epitope specificity and the affinity of antibodies are likely
to be essential for inhibitory activity, and are not measured by
standard ELISA. Furthermore, antibodies that can block the
inhibitory activity of other antibodies have been described [28,29],
and antibodies may also act by inhibiting the processing of
antigens required for erythrocyte invasion [29,30]. These findings
further emphasize the need for a greater understanding of growth-
inhibitory antibodies, which is likely to be essential for the
development and testing of blood-stage vaccines.
In order to understand the acquisition of human inhibitory
antibodies and their potential role in immunity, we have evaluated
the presence of inhibitory antibodies, and their association with
active infection and markers of blood-stage malaria exposure and
immunity, across different age groups and between populations
with different transmission levels. Furthermore, we evaluated the
relationship between inhibitory antibodies and antibodies to
recombinant MSP1-42, which is a leading vaccine candidate that
has been shown to induce growth-inhibitory antibodies [31,32,33],
and the C-terminal fragment of which (MSP1-19) has been
identified as a target of human inhibitory antibodies [11,14].
Methods
Study site and population
The main study site of Ngerenya, Kilifi district, Kenya has been
described previously [34,35]. Ngerenya experiences seasonal
malarial transmission following the ‘‘long’’ rains in May–July and
the ‘‘short’’ rains in November, and in 1997/1998 the predicted
entomologic innoculation rate (EIR) was 10 infective bites/person/
year. Serum samples collected cross-sectionally from two separate
Ngerenya cohorts were used. The first set (n=150) were selected
randomly from samples collected inSeptember 1998 from Ngerenya
adults and children (n=354), as part of a longitudinal cohort study
involving randomly selected households [34]. After baseline serum
sample collection, individuals were followed-up for 12 months by
active surveillance for symptomatic illness [34]. Study participants of
the Ngerenya 1998 cohort were divided into 3 age groups, in
concordance with age-associated incidence of clinical malaria in the
area [34]; 2–5 years, n=43; 6–14 years, n=57 and 18–81 year olds,
n=50.Thesecond setofsampleswascollectedfromthesamevillage
in October 2002 and comprised 237 children aged 1–8 years (1–5
years, n=129; 6–8 years, n=108). This subset was derived from a
larger cohort of children (,8 years, n=297) from randomly selected
Ngerenya households [36]. We included all serum samples that were
available from children $1 year of age.
Written informed consent was obtained from all participants, or
their guardians, in the study. Ethical approval was obtained from
the Ethics Committee of the Kenya Medical Research Institute,
Nairobi, Kenya and from the Human Research Ethics Commit-
tee, the Walter and Eliza Hall Institute, Melbourne, Australia.
Growth Inhibition Assays (GIAs)
The P. falciparum lines 3D7 and W2mef were cultured in vitro [37]
and synchronised by alternate day re-suspension in 5% D-sorbitol
(Sigma, St Louis, MO, USA) in water. Growth assays were
performed over two cycles of parasite replication and parasitemia
was measured using flow cytometry (FacsCalibur, Becton, Dick-
inson, Franklin Lakes, NJ) [13,38]. Assays were set-up with mature
trophozoites and schizonts, at 1% haematocrit and 0.3% starting
parasitemia (50 ml/well) in 96 well U-bottom culture plates (Becton
Dickinson, Franklin Lakes, USA) with pre-treated serum (5 ml) from
cohort members or from non-exposed United Kingdom or
Australian donors (n=7 to 10). On all plates, PBS was included as
a non-inhibitory control and 1F9 anti-AMA1 monoclonal antibody
(0.5 mg/ml) [39] was included as an inhibitory control. Parasite
growth for each sample is expressed relative to plate PBS controls.
All samples were tested in duplicate in two separate assays.
To remove potential growth inhibitors or enhancers, serum
samples were dialysed against PBS using 50 kDa MWCO micro-
dialysis tubes (2051, Chemicon, Temecula, CA, USA) and
subsequently reconstituted to original volume using centrifugal
concentration tubes (100 kDa MWCO; Pall Corp, Ann Arbor, MI,
USA) prior to testing in GIAs [38]. Purification of immunoglobulins
(Ig) was performed by ammonium sulphate precipitation, as
described [38].
Enzyme-Linked Immunosorbent Assays (ELISAs)
Serum IgG recognising components of schizont protein extract
and recombinant MSP1-42 was measured by ELISA [13].
Schizont protein extract was prepared from 3D7 cultures using
standard methods. Recombinant MSP1-42 and MSP1-19 (3D7)
proteins were kind gifts from Carole Long (NIH, Bethesda) and
Paul Gilson (WEHI, Melbourne), respectively. Samples were
tested in duplicate together with serum from 7–10 non-exposed
United Kingdom or Melbourne donors. Positive and negative
controls were included to allow standardisation.
Statistical analysis
Statistical analysis was performed using Stata Version 9
(StataCorp, College Station, Texas, USA). The association between
continuous variables was assessed using Students t-test or one-way
ANOVA,orbyWilcoxonrank-sumtestorKruskal-Wallistestwhere
appropriate. The association between categorical variables was
assessed using a chi-square test. Pearson and Spearman’s rank
correlation coefficients were used to assess the association between
two continuous variables. For the Ngerenya 1998 samples, the male
to female ratio varied across the three age groups so the association
between gender and the variables of interest was assessed separately
within each age group. Data exclusions were due to insufficient
sample for GIAs (Ngerenya 1998; 3D7, n=7 and W2mef, n=8),
and outliers (Ngerenya 1998; 3D7, n=3 and W2mef, n=4).
Survival analysis was performed using the Cox proportional hazards
method. Malaria was defined as symptoms of fever or observed fever
together with a parasitemia of .2500 parasites/ml.
Definitions. In the Ngerenya 1998 cohort, individuals with
antibody levels equal to or greater than the 75
th percentile value for
ELISA data were defined as‘highELISA responders’.Individualswhose
sera inhibited growth below the approximate median value for each
parasite line (3D7, ,45% growth [% of control], n=66; W2mef,
,35% growth, n=69) were defined as ‘high inhibitors’. To examine
breadth and strength of responses, individuals were defined as ‘strong
inhibitors’ (highly inhibitory of growth of both parasite lines (i.e. 3D7
,45% growth plus W2mef ,35% growth)), and ‘weak inhibitors’a s
those samples that were not strongly inhibitory of either 3D7 or
W2mef (3D7 $45% growth plus W2mef $35% growth). The
remaining samples were termed ‘intermediate inhibitors’.
Results
Acquisition of antibody to blood-stage antigens and
MSP1-42 increases with age
Among the 150 individuals selected from the Ngerenya 1998
cohort, there was an age-related decrease in the prevalence and
Antibodies against Malaria
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immunity in the population (Table 1) [34]. Samples from this
cohort were tested for IgG to schizont protein extract (a marker of
exposure to blood-stage malaria and acquired immunity) and
recombinant MSP1-42 (a major merozoite antigen and vaccine
candidate) by ELISA. Levels of IgG to schizont extract and MSP1-
42 were significantly correlated (Spearman’s rho, rs=0.79,
P,0.001). Median IgG levels to schizont extract and MSP1-42
increased with age in both aparasitemic and parasitemic
individuals (P,0.02) (Figure 1 A–D). In concordance, the
proportion of high responders to both antigens increased
significantly with age (Table 1). There was no significant
association between parasitemic status or gender and IgG levels
against schizont extract or MSP1-42.
Age and exposure-related pattern of acquisition of
growth-inhibitory antibodies
In contrast to the ELISA data, we did not observe a marked
increase in growth-inhibitory antibodies with increasing age among
the Ngerenya 1998 samples (Figure 2). Age associated profiles of
inhibition differed slightly for the two parasite lines despite a
significant positive correlation between growth of 3D7 and W2mef
(r=0.62, P,0.001). A small, statistically significant reduction in the
level of parasite growth inhibition with increased age was observed
for W2mef (P=0.007), but not for 3D7 (P=0.365). After stratifying
by parasitemic status, a significant association between reduced
growth inhibition of W2mef with age was seen for aparasitemic
participants only (P=0.002, Figure 2B). The proportion of highly
inhibitorysampleswasgreatestinyoungchildrenanddecreasedwith
age (3D7, P=0.294 and W2mef, P=0.006) (Table 1).
Examining associations between growth inhibitory antibodies
and exposure, a weak positive correlation was seen between
greater W2mef growth (i.e. reduced growth inhibition) and IgG to
schizont extract (rs=0.342, P,0.001; Fig. 3). This correlation was
stronger for aparasitemic compared to parasitemic individuals
(rs=0.375, P,0.001 and rs=0.119, P=0.153, respectively). No
correlation was seen between 3D7 parasite growth and IgG to
schizont extract (rs=20.01, P=0.887). Associations between
parasite growth and IgG to MSP1-42 were similar to those seen
for responses to schizont extract. A positive correlation between
W2mef growth (i.e. reduced growth inhibition) and IgG to MSP1-
42 was observed in both aparasitemic and parasitemic individuals
(rs=0.301, P=0.005 and rs=0.265, P=0.056, respectively). No
correlation existed between 3D7 growth and IgG to MSP1-42
among samples (rs=20.055, P=0.527). Additionally, no correla-
tion was found between antibodies to recombinant MSP1-19 and
inhibition of 3D7 growth (data not shown). Similar results were
obtained when the analysis was restricted to samples from children
(data not shown); there was a weak positive correlation between
antibodies to schizont extract or MSP1-42 and parasite growth
using W2mef, but not 3D7.
Mean levels of inhibition were not significantly different
between parasitemic versus aparasitemic individuals. In the 6
months following sample collection, 41 individuals (40 children, 1
adult) had at least one episode of symptomatic malaria, and
survival analysis was performed for children only (2–5 years,
n=43 and 6–14 years, n=57). As expected, older children had a
reduced risk of symptomatic malaria compared with younger
children (HR=0.24, P,0.001). There was no significant associ-
ation between inhibition of either 3D7 or W2mef growth by
samples and reduced risk of subsequent malaria with or without
adjustment for age.
The contrasting associations with age and exposure between
growth-inhibitory antibodies and total antimalarial antibodies led
us to further examine methods used to measure inhibitory
antibodies and to validate our findings. Immunoglobulins were
purified from an additional 52 sera samples of the Ngerenya 1998
cohort, chosen to achieve a group of children (#12 years, n=30)
for comparison with adults (.12 years, n=22), and tested for
growth inhibition in single and two-cycle growth-inhibition assays.
Again, we found little correlation between 3D7 or W2mef growth
and IgG to schizont extract (Fig. 4. A, B); there was a positive
correlation between W2mef growth and IgG to schizont extract for
aparasitemic individuals (rs=0.67, n=9; P=0.047). Inhibition of
growthwasnotsignificantlydifferentforadultscomparedtochildren
(Eg. mean W2mef growth6SD; adults=70.7621.8% versus
children=65.6618.7, P=0.365) or for high versus low responders
to schizont extract (71.3619.3% versus 66.6621.1%, respectively,
P=0.461). We typically performed GIAs over two cycles of parasite
replication because we have found this increases the sensitivity of the
assay[38].Wefound astrongcorrelationbetweenone and two-cycle
assays run in parallel for both W2mef and 3D7. The level of growth
inhibition was greater for two-cycle compared to one-cycle assays.
When samples were tested in single-cycle assays, there were no
significant associations between inhibition results and age, parasit-
emia or ELISA data. Additionally, a subset of 80 samples from the
Ngerenya 1998 cohort were independently dialysed and tested in
GIAs against 3D7 and W2mef. Similar to our earlier results, little
association with age was observed and mean inhibition of W2mef
was greater than for 3D7.
Breadth and strength of growth inhibition responses
according to age and exposure
To examine the breadth of response against both parasite lines
as well as the strength of growth inhibition among samples from
Ngerenya 1998 cohort we defined individuals as ‘strong inhibitors’
(n=45), ‘intermediate inhibitors’ (n=40) and ‘weak inhibitors’
(n=51) based on their activity against both parasite lines. The
proportion of strong inhibitors decreased with age (P=
0.009)(Table 1). In addition, the median [inter-quartile range,
IQR] IgG level to schizont extract was significantly lower for
strong inhibitors (0.19 [0.1–0.51]) compared to intermediate (0.19
[0.01–0.53]) or weak inhibitors (0.36 [0.21–0.78], P=0.037).
There was no evidence of association between breadth and
strength of a response with IgG towards MSP1-42 (P=0.178).
Profile of inhibitory antibodies in young children with
less malaria exposure
Toevaluate theinfluence ofdifferinglevels ofmalariatransmission
on the acquisition of inhibitory antibodies, we obtained 237 samples
that were collectedina cross-sectional surveyinthe samecommunity
in October 2002 from children aged 1–8 years. The level of malarial
transmission in the region was lower in 2002 compared to 1998 [40],
which is reflected in the lower proportion of parasitemic individuals
at the time of sample collection (Ngerenya 2002, 6.9% versus
Ngerenya 1998, 39.3%). To compare growth inhibition between the
two studies,analysis wasrestricted tochildren ofthe sameage in each
study (i.e. 2–8 years; median age of 5.1 years (Ngerenya 2002,
n=207) and 5 years (Ngerenya 1998, n=61)). Growth inhibition of
3D7 was significantly less in Ngerenya 2002 than Ngerenya 1998
(median [IQR] parasite growth as a percent of control was 100.6
[93.4–105.3] for Ngerenya 2002 versus 43.2 [37.1–48.6] for
Ngerenya 1998 samples; P,0.001). For all experiments, the level
of growth inhibition by cohort sera was significantly greater than that
seen for non-exposed control sera (P,0.001).
Because most Ngerenya 2002 samples were non-inhibitory
against 3D7, only an ‘‘inhibitory subset’’ comprised of the top 20%
Antibodies against Malaria
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,92%) was also tested against W2mef. Median W2mef growth in
this inhibitory subset of Ngerenya 2002 child samples was higher
(equivalent to reduced inhibition) than that observed for all
samples from children (aged 2–8 years) of the Ngerenya 1998
cohort (64.2 [55.8–72.4] versus 32.8 [27.9–36.6] respectively;
P,0.001). In considering only the 2002 samples, the inhibitory
subset of Ngerenya 2002 samples had higher IgG to schizont
extract compared with the remaining less-inhibitory (3D7 growth
$92%, n=191) Ngerenya 2002 samples (median [IQR] IgG: 0.16
[0.09–0.57], versus 0.13 [0.04–0.42], respectively, P=0.038).
However, there was no difference in age distribution between
the most inhibitory and less-inhibitory Ngerenya 2002 samples
(P=0.599). This suggests that exposure to blood-stage malaria,
rather than age per se, is the major determinant for the acquisition
of inhibitory antibodies in this cohort of children.
Discussion
Our findings demonstrate that children exposed to P. falciparum
can acquire growth-inhibitory antibodies at a young age after little
exposure to malaria. It appears that once these antibodies have been
acquiredtheyarenotboostedbysubsequentexposureintheclassical
manner described for antibodies to blood-stage antigens. In contrast
to the age-associated increase in antibodies to schizont extract and
MSP1-42, parasite growth-inhibitory antibodies tended to remain
stableordecreasewithage,despiteon-goingexposure,andtherewas
no substantial association with active infection. Antibodies to
Figure 1. Levels of IgG to schizont protein extract and recombinant MSP1-42, according to age and parasitemic status, among
samples from the Ngerenya 1998 cohort. A, B: Median absorbance (Optical Density, OD) to schizont protein extract and MSP1-42, respectively,
for aparasitemic participants (n=91). C, D: Median absorbance to schizont protein extract and MSP1-42, respectively, for parasitemic participants
(n=59). Sera were used at a dilution of 1:1000. Error bars represent the inter-quartile range. P values were calculated using a Kruskal-Wallis test. All
samples were tested in duplicate. The difference in median IgG levels for aparasitemic compared to parasitemic participants was not significant for
schizont extract or MSP1-42 (P=0.082 and P=0.14, respectively).
doi:10.1371/journal.pone.0003571.g001
Antibodies against Malaria
PLoS ONE | www.plosone.org 5 October 2008 | Volume 3 | Issue 10 | e3571schizont protein extract probably reflect cumulative exposure to
malaria and the overall level of blood-stage immunity. Similar to age
associations, there was a trend towards declining growth-inhibitory
activity as reactivity to blood-stage antigens in the schizont protein
extract increased, but the association was not strong. It is important
to note that inhibitory antibodies were clearly related to malaria
exposure as we found consistently greater inhibition by samples from
malaria-exposed individuals compared to non-exposed controls, and
inhibition wasgreateramong samples from children collected during
a period of higher malaria transmission. Examination of children in
the Ngerenya 2002 cohort with lower levels of malaria exposure
compared to those children in the Ngerenya 1998 cohort suggested
thatthe acquisition of inhibitory antibodies was ongoing at that time.
In the 2002 cohort there was a positive association between
antibodies to schizont extract and inhibitory activity and it appeared
that inhibitory activity in this group of children had not yet become
saturated. Findings among this cohort also confirmed that inhibitory
activity can be acquired at an early age and does not require
repeated exposure over several years.
The role of growth-inhibitory antibodies against blood-stage P.
falciparum in immunity to malaria, and their relevance to the
progression of disease in vivo, remains unclear. In our cohort,
growth-inhibitory antibodies were not associated with reduced risk
of symptomatic malaria. As expected, age was significantly
Figure 2. In-vitro growth inhibition of parasite lines 3D7 and W2mef, according to parasitemic status, among samples from the
Ngerenya 1998 cohort. A, B: Mean growth of 3D7 and W2mef, respectively, for aparasitemic participants. C, D: Mean growth of 3D7 and W2mef,
respectively, for parasitemic participants. Growth is expressed relative to control (PBS). Error bars represent standard deviation. P values were
calculated using a one-way ANOVA. All samples were tested in duplicate in two separate assays. For all samples, including parasitemic and
aparasitemic individuals together, mean growth (%, 6SD) was: W2mef (n=138) 31.866.5, 2–5 years; 35.169.0, 6–14 years; 38.1610.3, 18–81 years;
3D7 (n=140) 42.468.3, 2–5 years; 44.2612.4, 6–14 years; 45.467.5, 18–81 years.
doi:10.1371/journal.pone.0003571.g002
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was not positively associated with age. The acquisition of
inhibitory antibodies at an early age and the relatively stable
levels of inhibitory antibodies through childhood suggest that a
potential role for these responses in protection from early
childhood malaria should be considered. Immunity to severe
malaria is acquired relatively quickly after little exposure whereas
effective immunity to mild symptomatic malaria is acquired
significantly later [2]. It is possible that early immune responses,
such as the acquisition of growth-inhibitory antibodies, are
important for immunity to severe malaria. Further studies are
needed to test this hypothesis.
These findings have important implications for development and
evaluation of candidate blood-stage vaccines. It is assumed that
antibodiestomerozoiteantigensshouldinduceinhibitoryantibodies,
but the relevance of this response to immunity in humans remains to
beestablished.Vaccine trialswithmerozoite antigensareusuallyfirst
done among older children with prevention of symptomatic malaria
as the end-point; this may not be an appropriate strategy to evaluate
these responses. Our results suggest that individual inhibitory
antibody responses do not continue to increase in effect once they
are acquired, which occurs following limited exposure. This may
explain recent findings that immunization of malaria-exposed adults
with AMA1 boosted total IgG to recombinant AMA1, but did not
Figure 3. The association between in vitro growth of parasite lines 3D7 or W2mef and IgG measured by ELISA, according to
parasitemic status, for the Ngerenya 1998 cohort. A, B: Correlation between ELISA response to schizont extract and 3D7 or W2mef growth,
respectively. C, D: Correlation between ELISA response to MSP1-42 and 3D7 or W2mef growth, respectively. rs values represent Spearman’s rank
correlation coefficients. Results for aparasitemic and parasitemic individuals are represented by black or grey diamonds, respectively. Samples used in
growth-inhibition assays were dialysed serum.
doi:10.1371/journal.pone.0003571.g003
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similarly found that inhibitory antibodies tended to be lower among
adults than children [42], and recent studies by Dent et al. in western
Kenya report maximum inhibitory activity among young children,
which subsequently declines with increasing age [43]. Two prior
studies also found no association between growth inhibition by
dialysed serum [42] or whole serum [25] and risk of mild malaria
episodes, as we found here. On the other hand, some data suggests
growth-inhibitory antibodies may contribute to a reduced risk of
reinfection. In western Kenya, MSP1-19 specific inhibitory activity
ofwhole serum andtotalgrowth-inhibitoryactivityofdialysedserum
was associated with reduced risk of reparasitisation after treatment
[23,43]. Further studies are needed to focus on possible associations
between inhibitory antibodies and protection from symptomatic
malaria in early childhood.
The use of untreated serum/plasma by some studies may have
affected the measurement of inhibitory antibodies and the
associations with clinical parameters. Non-specific growth-inhibitory
factors, such as antimalarials, have been reported in untreated
samples [38,44]; therefore we dialysis-treated all samples prior to use
in our study. Comparable inhibitory effects of dialysed serum versus
immunoglobulin isolated from serum have been shown previously
[38]. In the present study, similar associations between growth-
inhibitory activity of samples and other parameters were found using
dialysed serum or purified immunoglobulins suggesting that
antibody rather than other serum factors is the major mediator of
growth inhibition in our assays. Chloroquine was the drug most
likely to have been used for treatment of malaria in the population at
that time [45] and we confirmed that chloroquine was removed by
serum dialysis (data not shown). Furthermore, we found that W2mef
was resistant to common anti-malarial drugs at concentrations that
could be expected in serum following treatment for malaria
(McCallum, Richards, Wilson, unpublished data). Therefore the
presence of antimalarials in samples is unlikely to be a factor
influencing our growth inhibition results.
In our studies, associations between age, exposure, and inhibitory
antibodies were established by extensive testing of two different
parasite lines. Additionally, no association between age and level of
growth inhibitory activity was found using W2mef variants with
different invasion phenotypes (Persson, McCallum, Beeson, unpub-
lished data). Interestingly, W2mef was consistently inhibited to a
greater degree than 3D7. Differences in the inhibitory activity
against different parasite lines may be explained by differences in the
level ofexposure inthe population tokey epitopes expressed bythese
isolates. 3D7 and W2mef are known to differ in allelic variants of
several important antigens, such as AMA1, and use different ligands
for erythrocyte invasion [12,46]. Recent studies suggest that
variation in the use of erythrocyte invasion pathways may act as a
mechanism that facilitates immune evasion [13].
Differences in the acquisition and maintenance of ELISA-
measured antibodies compared with growth-inhibitory antibodies
may be explained by several factors. Human antibody responses to
recombinant merozoite antigens have been reported to be short
lived among children [47,48], but appear to stabilise in older
children and adults; this response needs to be investigated with
respect to inhibitory antibodies. Maintenance of inhibitory
antibodies at a sufficient concentration for functional activity
may require exposure to a threshold parasite density that is
reached in young children during infection, but not in adults and
older children who more effectively control and suppress parasite
density. A further consideration is that the polyclonal antibody
response to merozoite antigens includes inhibitory and non-
inhibitory antibodies; repeated exposure may lead to non-
inhibitory antibodies reaching a greater concentration or higher
affinity than inhibitory antibodies, especially if inhibitory epitopes
are fewer in number than non-inhibitory epitopes. Others have
reported the acquisition of antibodies that can block the activity of
inhibitory antibodies [28], which may impede the development of
inhibitory activity with increased exposure; presently, this effect is
not well understood. Antibodies to merozoite antigens may also
act by antibody-dependent cellular inhibition of parasite growth
rather than by directly inhibiting invasion [49].
The lack of association between high levels of IgG to recombinant
MSP1-42orMSP1-19andgrowth-inhibitoryactivityraisesconcerns
Figure 4. Correlation between IgG to schizont protein extract measured by ELISA and in vitro growth inhibition using purified
immunoglobulins. A 3D7 parasite line. B W2mef parasite line. Samples used in the assays were immunoglobulins purified using ammonium
sulphate precipitation from Ngerenya 1998 serum samples (n=52). rs represents Spearman’s rank correlation coefficients.
doi:10.1371/journal.pone.0003571.g004
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vaccine-induced immunity. The sum effects of multiple antibodies
towards different merozoite antigens in serum samples may
confound associations between measurements of growth inhibition
and antibodies to a single antigen. However, in our study children
with high ELISA antibodies to MSP1-42, or MSP1-19, often lacked
inhibitory activity, suggesting that ELISA is a not a reliable measure
of inhibitory activity. Vaccination of monkeys with MSP1-42
induced growth-inhibitory antibodies and protected against P.
falciparum challenge [33]. However, vaccination of human volunteers
with recombinant MSP1-42 induced inhibitory antibodies only in a
subset of individuals, despite high rates of seroconversion to the
recombinant antigen [31,32]. Further studies are clearly needed to
understand the relationship between antibody reactivity in standard
immunoassays and growth-inhibitory activity.
Thesefindingshaveimportantimplicationsforunderstandingand
measuring immunity, and for the development and evaluation of
blood-stage vaccines. Our results suggest that the acquisition of
functional antibodies differs from that which has been predicted
from studies of acquired immunity using standard immunoassays.
Antibodies can be acquired at an early age after limited exposure to
malaria, but do not demonstrate continued boosting or enhance-
ment with ongoing exposure. Furthermore, antibodies measured by
ELISA to potential targets of inhibitoryantibodies,suchas MSP1-42
or MSP1-19, showed little correlation with growth-inhibitory
activity. Results from this work suggest that future investigations
on inhibitory antibodies are needed among younger children at the
time when they are first experiencing malaria episodes.
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